{
    "clinical_study": {
        "@rank": "109247", 
        "arm_group": [
            {
                "arm_group_label": "Placebo & propofol", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Pretreatment with normal saline before injection of propofol"
            }, 
            {
                "arm_group_label": "esmolol 0.05 mg/kg & propofol", 
                "arm_group_type": "Experimental", 
                "description": "Pretreatment with esmolol 0.05 mg/kg before injection of propofol"
            }, 
            {
                "arm_group_label": "esmolol 1 mg/kg & propofol", 
                "arm_group_type": "Experimental", 
                "description": "Pretreatment with esmolol 1 mg/kg before injection of propofol"
            }, 
            {
                "arm_group_label": "remifentanil 0.35 ug/kg & propofol", 
                "arm_group_type": "Active Comparator", 
                "description": "Pretreatment with remifentanil 0.35 ug/kg before injection of propofol"
            }
        ], 
        "brief_summary": {
            "textblock": "Pain on injection of propofol is a common side effect. The present study was designed to\n      investigate the effect of esmolol on pain on propofol injection and to compare it with\n      remifentanil and placebo."
        }, 
        "brief_title": "Esmolol Pretreatment on Pain During Injection of Propofol", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "In a double-blind, prospective trial, 120 patients scheduled to undergo elective surgery\n      were randomized to receive normal saline (n=30), remifentanil 0.35 \u03bcg/kg (n=30), esmolol 0.5\n      mg/kg (n=30), or Esmolol 1mg/kg (n=30) as pretreatment. Thirty seconds after pretreatment,\n      25% of the total calculated dose of propofol (2 mg/kg) was administrated into a dorsal hand\n      vein. Ten seconds after propofol had been given at the rate of 0.5 ml/sec pain was assessed\n      on a four-point scale (0=none, 1 = mild, 2= moderate, 3= severe)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients aged 19-60 years, American Society of Anesthesiologists (ASA) physical\n             status I and II, scheduled for elective surgery under general anesthesia\n\n        Exclusion Criteria:\n\n          -  Patients with cardiovascular, neurological or psychiatric disorder problem, patients\n             who received the analgesic or sedative medications within the last 24 hours, and\n             pregnancy were excluded"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885364", 
            "org_study_id": "KNUH 2013-05-003-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo & propofol", 
                "description": "intravenous injection with normal saline before injection of propofol", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline"
            }, 
            {
                "arm_group_label": [
                    "esmolol 0.05 mg/kg & propofol", 
                    "esmolol 1 mg/kg & propofol"
                ], 
                "description": "intravenous injection with remifentanil 0.5 mg/kg before injection of propofol", 
                "intervention_name": "Esmolol", 
                "intervention_type": "Drug", 
                "other_name": "breviblock"
            }, 
            {
                "arm_group_label": "remifentanil 0.35 ug/kg & propofol", 
                "description": "intravenous injection with remifentanil 0.35 ug/kg before injection of propofol", 
                "intervention_name": "Remifentanil", 
                "intervention_type": "Drug", 
                "other_name": "ultiva"
            }, 
            {
                "arm_group_label": [
                    "Placebo & propofol", 
                    "esmolol 0.05 mg/kg & propofol", 
                    "esmolol 1 mg/kg & propofol", 
                    "remifentanil 0.35 ug/kg & propofol"
                ], 
                "description": "intravenous injection after pretreatment", 
                "intervention_name": "propofol", 
                "intervention_type": "Drug", 
                "other_name": "diprivan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Propofol", 
                "Remifentanil", 
                "Esmolol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "esmolol", 
            "pain", 
            "propofol", 
            "remifentanil"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "location": {
            "contact": {
                "email": "pakkibum@naver.com", 
                "last_name": "Kibum Park, Dr", 
                "phone": "82-53-420-5863"
            }, 
            "facility": {
                "address": {
                    "city": "Daegu", 
                    "country": "Korea, Republic of", 
                    "zip": "700-721"
                }, 
                "name": "Kyungpook National University Hospital"
            }, 
            "investigator": {
                "last_name": "Younghoon Jeon, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Esmolol Pretreatment on Pain During Injection of Propofol", 
        "overall_official": {
            "affiliation": "Kyungpook National University", 
            "last_name": "Younghoon Jeon, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Thirty seconds after pretreatment, 25% of the total calculated dose of propofol (2 mg/kg) was administrated into a dorsal hand vein. Ten seconds after injection of propofol, pain was assessed on a four-point scale (0=none, 1 = mild, 2= moderate, 3= severe).", 
            "measure": "Pain on injection of propofol", 
            "safety_issue": "Yes", 
            "time_frame": "10 seconds after injection of 25% of the total calculated dose of propofol (2 mg/kg)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885364"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kyungpook National University", 
            "investigator_full_name": "Younghoon Jeon", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Kyungpook National University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyungpook National University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}